WO1999067384A3 - Prostate cancer-associated genes - Google Patents

Prostate cancer-associated genes Download PDF

Info

Publication number
WO1999067384A3
WO1999067384A3 PCT/US1999/013524 US9913524W WO9967384A3 WO 1999067384 A3 WO1999067384 A3 WO 1999067384A3 US 9913524 W US9913524 W US 9913524W WO 9967384 A3 WO9967384 A3 WO 9967384A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
associated genes
provides
genes
agonists
Prior art date
Application number
PCT/US1999/013524
Other languages
French (fr)
Other versions
WO1999067384A2 (en
Inventor
Michael G Walker
Wayne Volkmuth
Tod M Klingler
Einat A Sprinzak
Original Assignee
Incyte Pharma Inc
Michael G Walker
Wayne Volkmuth
Tod M Klingler
Einat A Sprinzak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharma Inc, Michael G Walker, Wayne Volkmuth, Tod M Klingler, Einat A Sprinzak filed Critical Incyte Pharma Inc
Priority to AU48235/99A priority Critical patent/AU4823599A/en
Priority to JP2000556027A priority patent/JP2002518048A/en
Priority to CA002331769A priority patent/CA2331769A1/en
Priority to EP99931806A priority patent/EP1088072A2/en
Publication of WO1999067384A2 publication Critical patent/WO1999067384A2/en
Publication of WO1999067384A3 publication Critical patent/WO1999067384A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides novel prostate cancer-associated genes and polypeptides encoded by those genes. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing diseases.
PCT/US1999/013524 1998-06-22 1999-06-15 Prostate cancer-associated genes WO1999067384A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU48235/99A AU4823599A (en) 1998-06-22 1999-06-15 Prostate cancer-associated genes
JP2000556027A JP2002518048A (en) 1998-06-22 1999-06-15 Prostate cancer-related genes
CA002331769A CA2331769A1 (en) 1998-06-22 1999-06-15 Prostate cancer-associated genes
EP99931806A EP1088072A2 (en) 1998-06-22 1999-06-15 Prostate cancer-associated genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10261598A 1998-06-22 1998-06-22
US09/102,615 1998-06-22

Publications (2)

Publication Number Publication Date
WO1999067384A2 WO1999067384A2 (en) 1999-12-29
WO1999067384A3 true WO1999067384A3 (en) 2000-04-06

Family

ID=22290762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013524 WO1999067384A2 (en) 1998-06-22 1999-06-15 Prostate cancer-associated genes

Country Status (5)

Country Link
EP (1) EP1088072A2 (en)
JP (1) JP2002518048A (en)
AU (1) AU4823599A (en)
CA (1) CA2331769A1 (en)
WO (1) WO1999067384A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
JP2002527758A (en) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド Methods for diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000071711A2 (en) * 1999-05-20 2000-11-30 Fahri Saatcioglu Differentially expressed genes in prostate cancer
CO5450246A1 (en) * 1999-07-13 2004-10-29 Smithkline Beecham Corp VACCINE
WO2001034802A2 (en) * 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US20020009455A1 (en) * 2000-04-27 2002-01-24 Ted Lau DNA encoding a novel PROST 03 polypeptide
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP2295606A1 (en) * 2000-11-28 2011-03-16 Wyeth LLC Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP1988097A1 (en) * 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004092213A1 (en) * 2003-04-08 2004-10-28 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Gene expressed in prostate cancer, methods and use thereof
CL2008001491A1 (en) 2007-05-24 2008-11-28 Glaxosmithkline Biolog Sa Freeze-dried composition comprising one or more antigens and a toll 9 receptor agonist (tlr9); and preparation procedure.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020117A1 (en) * 1996-11-05 1998-05-14 Incyte Pharmaceuticals, Inc. Prostate-specific kallikrein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020117A1 (en) * 1996-11-05 1998-05-14 Incyte Pharmaceuticals, Inc. Prostate-specific kallikrein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOK L J ET AL: "ISOLATION OF CDNAS THAT ARE DIFFERENTIALLY EXPRESSED BETWEEN ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT PROSTATE CARCINOMA CELLS USING DIFFERENTIAL DISPLAY PCR", PROSTATE, vol. 26, no. 4, 1 April 1995 (1995-04-01), pages 213 - 224, XP000611577 *
HILLIER ET AL.: "The WashU-Merck EST Project", EMBL ACC NO: AA149579, 15 December 1996 (1996-12-15), XP002120632 *
ROBINSON ET AL.: "A tyrosine kinase profile of prostate carcinoma", PROC. NATL. ACAD. SCI. USA, vol. 93, June 1996 (1996-06-01), pages 5958 - 5962, XP002120631 *
STRAUSBERG ET AL.: "National cancer institute,cancer genome anatomy project (CGAP)", EMBL ACC NO: AA689456, 19 December 1997 (1997-12-19), XP002120633 *
SUZUKI ET AL.: "Changes in template-engaged and free RNA polymerase I activities in isolated nuclei from rat ventral prostates after treatment with testosterone and cycloheximide", J.BIOCHEM., vol. 95, no. 5, May 1984 (1984-05-01), pages 1389 - 1398, XP002120634 *

Also Published As

Publication number Publication date
AU4823599A (en) 2000-01-10
CA2331769A1 (en) 1999-12-29
EP1088072A2 (en) 2001-04-04
JP2002518048A (en) 2002-06-25
WO1999067384A2 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
WO2000029574A3 (en) Inflammation-associated genes
WO1999036550A3 (en) Human protease molecules
WO1999067384A3 (en) Prostate cancer-associated genes
WO2000061622A3 (en) Genes associated with diseases of the kidney
WO2000050588A3 (en) Genes associated with diseases of the colon
WO2000034477A3 (en) Neuron-associated proteins
WO2000018922A8 (en) Human carbohydrate-associated proteins
WO2000009709A3 (en) Proteases and associated proteins
WO2000012703A3 (en) Protein transport-associated molecules
WO2000017355A3 (en) Human cytoskeleton associated proteins
WO2000052151A3 (en) Human secretory proteins
WO2001016334A3 (en) Human hydrolytic enzymes
WO2000005374A3 (en) Molecules associated with cell proliferation
WO2000021986A3 (en) Matrix-remodeling genes
WO2000000594A3 (en) Human transferases
WO2001044448A3 (en) Human oxidoreductase proteins
WO2000020604A3 (en) Oxidoreductase molecules
WO2000040722A3 (en) Insulin-synthesis genes
WO2000042201A3 (en) Human peptidases
WO1999041373A3 (en) Human transport-associated molecules
WO2000028045A3 (en) Human hydrolase proteins
WO2000008155A3 (en) Human receptor-associated proteins
WO1999049037A3 (en) Protein phosphatase-related molecules
WO2001018042A3 (en) Apoptosis proteins
WO2000024911A3 (en) Human phospholipases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2000 556027

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2331769

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999931806

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999931806

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999931806

Country of ref document: EP